Search Results - "Chang, Charissa Y"

Non-alcoholic fatty liver disease by TUYAMA, Ana C., CHANG, Charissa Y.

“…Non‐alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world. It is closely associated with metabolic syndrome. The…”
Get full text

Changing Epidemiology of Hepatocellular Adenoma in the United States: Review of the Literature by Chang, Charissa Y., Hernandez-Prera, Juan C., Roayaie, Sasan, Schwartz, Myron, Thung, Swan N.

“…Hepatocellular adenoma (HCA) is a benign neoplasm arising from hepatocytes. There is evidence that the inflammatory subtype may be associated with obesity and…”
Get full text

AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma by Altayar, Osama, Shah, Raj, Chang, Charissa Y., Falck-Ytter, Yngve, Muir, Andrew J.

Get full text

Progenitor cell markers predict outcome of patients with hepatocellular carcinoma beyond Milan criteria undergoing liver transplantation by Miltiadous, Oriana, Sia, Daniela, Hoshida, Yujin, Fiel, Maria Isabel, Harrington, Andrew N, Thung, Swan N, Tan, Poh Seng, Dong, Hui, Revill, Kate, Chang, Charissa Y, Roayaie, Sasan, Byrne, Thomas J, Mazzaferro, Vincenzo, Rakela, Jorge, Florman, Sander, Schwartz, Myron, Llovet, Josep M

“…Graphical abstract…”
Get full text

Molecular approaches to treatment of hepatocellular carcinoma by Lachenmayer, Anja, Alsinet, Clara, Chang, Charissa Y, Llovet, Josep M

“…Abstract Hepatocellular carcinoma (HCC) remains a highly complex disease resistant to commonly used chemotherapy and radiotherapy. As the sixth most common…”
Get full text

Understanding the relationship between PNPLA3, NAFLD and insulin resistance: do ethnic differences bring more questions or more answers? by Chang, Charissa Y.

Get full text

TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts by Bercu, Zachary L, Fischman, Aaron M, Kim, Edward, Nowakowski, F Scott, Patel, Rahul S, Schiano, Thomas D, Chang, Charissa Y, Lookstein, Robert A

“…OBJECTIVE. This single-center study evaluated the use of expanded polytetrafluoroethylene (ePTFE)-covered stent-grafts for transjugular intrahepatic…”
Get full text

Mitochondria in nonalcoholic fatty liver disease by Caldwell, Stephen H, Chang, Charissa Y, Nakamoto, Robert K, Krugner-Higby, Lisa

“…Nonalcoholic fatty liver (NAFL) is associated with fundamental issues of fat metabolism and insulin resistance. These abnormalities have been linked to…”
Get more information

A patient with chronic hepatitis B and regression of fibrosis during treatment by Chang, Charissa Y, Martin, Paul, Fotiadu, Anastasia, Hytiroglou, Prodromos

“…We present a patient with HBeAg-negative chronic hepatitis B, in whom significant regression of hepatic fibrosis was achieved after a lengthy antiviral…”
Get more information

A case of quadruple viral infections and elevated aminotransferase activities by Bhasin, Devina, Zhang, Xuchen, Ward, Stephen C, Chang, Charissa Y

“…A 40-year-old man with human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) infection was referred for evaluation of…”
Get more information

Therapy of NAFLD: Antioxidants and Cytoprotective Agents by Chang, Charissa Y, Argo, Curtis K, Al-Osaimi, Abdullah M. S, Caldwell, Stephen H

“…Lipid peroxidation and secondary cellular injury are the dominant mechanism in the transition from relatively stable hepatic steatosis to potentially…”
Get full text

Use of splenic artery embolization to relieve tense ascites following liver transplantation in a patient with paroxysmal nocturnal hemoglobinuria by Chang, Charissa Y., Singal, Ashwani K., Ganeshan, Sri V., Schiano, Thomas D., Lookstein, Robert, Emre, Sukru

“…Recurrent venous thrombosis following liver transplantation for Budd‐Chiari syndrome is common, particularly in the setting of an underlying myeloproliferative…”
Get full text

Obesity and liver cancer mortality in Asia: The Asia Pacific Cohort Studies Collaboration by Batty, G. David, Barzi, Federica, Huxley, Rachel, Chang, Charissa Y, Jee, Sun Ha, Jamrozik, Konrad, Kim, Hyeon Chang, Fang, Xianghua, Lam, Tai H, Woodward, Mark

“…Abstract While obesity is associated with liver cancer in studies from western societies, the paucity of data from Asia limits insights into its aetiological…”
Get full text

Patient with hepatitis B and alcoholic liver disease before and after liver transplantation by Ward, Stephen C, Chang, Charissa Y, Peng, Lan, Liu, Lawrence U

“…We present the case of a patient with hepatitis B virus infection and alcohol use (30 g/day by self-report) who developed cirrhosis and proceeded to liver…”
Get more information

Enlarged Hepatocytes in NAFLD Examined with Osmium Fixation: Does Microsteatosis Underlie Cellular Ballooning in NASH? by Caldwell, Stephen H, Redick, Jan A, Chang, Charissa Y, Davis, Christine A, Argo, Curtis K, Al Osaimi, K Abdullah M S

Get full text

Acetaminophen Hepatotoxicity: Current Management by Tan, Hui‐Hui, Chang, Charissa Y., Martin, Paul

Get full text

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC by Lencioni, Riccardo, Montal, Robert, Torres, Ferran, Park, Joong-Won, Decaens, Thomas, Raoul, Jean-Luc, Kudo, Masatoshi, Chang, Charissa, Ríos, José, Boige, Valerie, Assenat, Eric, Kang, Yoon-Koo, Lim, Ho-Yeong, Walters, Ian, Llovet, Josep M

“…Graphical abstract…”
Get full text

Understanding the relationship between PNPLA 3, NAFLD and insulin resistance: do ethnic differences bring more questions or more answers? by Chang, Charissa Y.

Get full text

953 – High Efficacy and Improvement in Cpt Class with Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients with Cpt C Decompensated Cirrhosis by Flamm, Steven L., Lawitz, Eric, Borg, Brian, Charlton, Michael, Landis, Charles, Reddy, K. Rajender, Shiffman, Mitchell L., Samuel, Didier, Alsina, Angel, Chang, Charissa Y., Ravendhran, Natarajan, Zhang, Gulan, Cheinquer, Nelson, Moon, Scott, Spellman, James, Stamm, Luisa, Gaggar, Anuj, Hezode, Christophe

Get full text

Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results by Bichoupan, Kian, Tandon, Neeta, Crismale, James F, Hartman, Joshua, Del Bello, David, Patel, Neal, Chekuri, Sweta, Harty, Alyson, Ng, Michel, Sigel, Keith M, Bansal, Meena B, Grewal, Priya, Chang, Charissa Y, Leong, Jennifer, Im, Gene Y, Liu, Lawrence U, Odin, Joseph A, Bach, Nancy, Friedman, Scott L, Schiano, Thomas D, Perumalswami, Ponni V, Dieterich, Douglas T, Branch, Andrea D

“…To assess the real-world effectiveness and cost of simeprevir (SMV), and/or sofosbuvir (SOF)-based therapy for chronic hepatitis C virus (HCV) infection. The…”
Get full text